Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
3.31% $1.250
America/New_York / 18 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 142.92 mill |
EPS: | -0.640 |
P/E: | -1.950 |
Earnings Date: | May 09, 2024 |
SharesOutstanding: | 114.33 mill |
Avg Daily Volume: | 0.168 mill |
RATING 2024-04-18 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Strong Buy | |
P/E: | Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -1.950 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.10x |
Company: PE -1.950 | industry: PE 18.71 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 1.142 - 1.358 ( +/- 8.64%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-05 | Vazquez Chris | Buy | 22 | Series A Non-Voting Convertible Preferred Stock |
2024-04-05 | Strobeck Matthew | Buy | 7 392 | Series A Non-Voting Convertible Preferred Stock |
2024-04-05 | Strobeck Matthew | Buy | 1 304 | Series A Non-Voting Convertible Preferred Stock |
2024-04-05 | Schuler Jack W | Buy | 2 174 | Series A Non-Voting Convertible Preferred Stock |
2024-04-05 | Pestano Gary Anthony | Buy | 22 | Series A Non-Voting Convertible Preferred Stock |
INSIDER POWER |
---|
88.91 |
Last 100 transactions |
Buy: 13 131 293 | Sell: 601 205 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.250 (3.31% ) |
Volume | 0.0453 mill |
Avg. Vol. | 0.168 mill |
% of Avg. Vol | 27.05 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.